Novel Treatment of Keloids and Hypertrophis Scars

Information

  • Research Project
  • 6736994
  • ApplicationId
    6736994
  • Core Project Number
    R43AR049972
  • Full Project Number
    1R43AR049972-01A1
  • Serial Number
    49972
  • FOA Number
  • Sub Project Id
  • Project Start Date
    6/18/2004 - 20 years ago
  • Project End Date
    6/30/2006 - 18 years ago
  • Program Officer Name
    IKEDA, RICHARD A.
  • Budget Start Date
    6/18/2004 - 20 years ago
  • Budget End Date
    6/30/2006 - 18 years ago
  • Fiscal Year
    2004
  • Support Year
    1
  • Suffix
    A1
  • Award Notice Date
    6/18/2004 - 20 years ago

Novel Treatment of Keloids and Hypertrophis Scars

DESCRIPTION (provided by applicant): Treatment of hypertrophic scars and keloids is time consuming, expensive, and has few consistently successful approaches. Hypertrophic scars and keloids are often treated with intralesional injection, pressure therapy, or excision. Unfortunately, these treatment modalities are invasive, painful, or inconvenient, and often unsuccessful. Silicone gel sheeting has been used successfully in the treatment of scarring, but the dressings can be difficult to affix and are associated with local side effects and cosmetic deficiencies that negatively impact compliance and patient satisfaction. The goal of this project is to demonstrate the feasibility of using a novel film forming technology as an alternative to silicone sheeting for the treatment of hypertrophic scars and keloids. This project offers an innovative polymer-based technology to overcome the limitations of silicone sheeting. The product is expected to be commercially successful based on its inherent low cost, ease of use, superior cosmetic attributes, and improved outcomes. The following specific aims will be pursued: Specific Aim 1. Formulate Coatings for the Treatment of Hypertrophic Scars and Keloids Specific Aim 2. Demonstrate Efficacy of Coatings in a Human Clinical Trial.

IC Name
NATIONAL INSTITUTE OF ARTHRITIS AND MUSCULOSKELETAL AND SKIN DISEASES
  • Activity
    R43
  • Administering IC
    AR
  • Application Type
    1
  • Direct Cost Amount
  • Indirect Cost Amount
  • Total Cost
    113828
  • Sub Project Total Cost
  • ARRA Funded
  • CFDA Code
    846
  • Ed Inst. Type
  • Funding ICs
    NIAMS:113828\
  • Funding Mechanism
  • Study Section
    ZRG1
  • Study Section Name
    Special Emphasis Panel
  • Organization Name
    BIOMEDICAL DEVELOPMENT CORPORATION
  • Organization Department
  • Organization DUNS
  • Organization City
    SAN ANTONIO
  • Organization State
    TX
  • Organization Country
    UNITED STATES
  • Organization Zip Code
    782163610
  • Organization District
    UNITED STATES